Kripthonite Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Kripthonite Therapeutics is pioneering a novel approach to overcome a fundamental challenge in oncology: treatment-resistant hypoxic cancer cells. Its lead asset, PH1154, is a hypoxia-targeting macrocycle (HTMC) that disrupts the unique energy metabolism of oxygen-starved cells, leading to selective cell death. Strong preclinical data, particularly in combination with radiotherapy, demonstrates the potential to significantly improve tumor eradication and survival. The company is a private, preclinical-stage biotech seeking partnerships to advance its program into clinical trials.

Oncology

Technology Platform

Platform of Hypoxia-Targeting Macrocycles (HTMCs). Small molecules designed to be selectively activated in low-oxygen environments, where they disrupt mitochondrial metabolism in hypoxic cancer cells, causing selective cell death. Differentiated from traditional hypoxia-activated prodrugs (HAPs) by its non-chemotherapy, biochemically induced mechanism targeting a fundamental metabolic vulnerability.

Opportunities

The therapy targets hypoxia, a universal feature of solid tumors and a key driver of treatment resistance, creating a potential market across multiple major cancer indications.

Its combination-based strategy could integrate with and enhance the efficacy of existing, widely used radiotherapy, chemotherapy, and immunotherapy regimens.

Success would address a significant unmet need for millions of patients annually and establish a new standard of care in oncology.

Risk Factors

High translational risk moving from compelling preclinical models to safe and effective human trials.

The company is pre-revenue and reliant on securing partnership or venture funding to advance its costly clinical development.

Faces competition from other approaches targeting the tumor microenvironment and must prove its novel mechanism offers superior efficacy or safety to overcome historical failures in targeting hypoxia.

Competitive Landscape

Competition includes historical and next-generation Hypoxia-Activated Prodrugs (HAPs) from companies like Threshold Pharmaceuticals (evofosfamide) and others, though Kripthonite's mechanism is distinct. Broader competition comes from other modalities aiming to overcome treatment resistance, including angiogenesis inhibitors, immunotherapy combinations, and other metabolic pathway inhibitors. Kripthonite's key differentiator is its first-in-class HTMC mechanism designed for selective hypoxic cell killing without delivering traditional chemotherapy.

More companies in Small Molecule Drugs →More companies in Denmark →